Four individual GLP-1 receptor agonists have now demonstrated MACE superiority in their dedicated cardiovascular outcome trials: Liraglutide: LEADER trial Semaglutide: SUSTAIN-6 and the landmark SELECT trial Dulaglutide: REWIND trial Albiglutide: HARMONY trial The SELECT trial deserves special attention because it broke entirely new ground
Lamotrigine can be used for the research of epilepsy, focal seizure, et al + channels [1] [2]
federal government requires OUD patients to visit federally approved Opioid Treatment Programs (OTPs) for their daily dose of methadone
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis MARKET DYNAMICS Stringent cost and payer controls OPPORTUNITIES Impact Level Increasing studies on oral GLP-1 Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis Rapid expansion of manufacturing capacity is driving growth across the pharmaceutical market, especially for high-demand drugs like GLP-1 analogs
This difference in price is due to a practice known as microdosing, which involves taking smaller doses of a drug as way to cut prices for the patient
Bruning JC, Fenselau H